Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Gastrointestinal 2Gynecologic 1CNS 1

Conditions

Colorectal Neoplasms 5Breast Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × NVP-BKM120 × Gastrointestinal × Clear all
NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Novartis

Phase 1 Completed
113 enrolled
BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Array BioPharma

Phase 1 Completed
89 enrolled
BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡